Table 4.
Characteristics of metastatic colorectal cancer patients receiving targeted biologic in first line and multivariable regression for factors associated with the receipt of targeted biologics
| Characteristics | mCRC patients who received first-line treatment, N (column %) | mCRC patients who received first-line with targeted biologic, N (row %) | Receipt of first-line targeted biologic, multivariable OR (95 % CI) |
|---|---|---|---|
| Total | N = 4418 | N = 2077 | |
| Age (years) | |||
| 65–69 | 1333 (30.2) | 664 (49.8) | Referent |
| 70–74 | 1190 (26.9) | 555 (46.6) | 0.88 (0.74–1.04) |
| 75–79 | 1022 (23.1) | 451 (44.1) | 0.77 (0.64–0.91)* |
| 80–84 | 627 (14.2) | 280 (44.7) | 0.78 (0.64–0.96)* |
| 85+ | 246 (5.6) | 127 (51.6) | 0.99 (0.74–1.33) |
| Race/ethnicity | |||
| Caucasians | 3693 (83.6) | 1732 (46.9) | Referent |
| African Americans | 382 (8.7) | 181 (47.4) | 0.94 (0.74–1.20) |
| Others | 343 (7.8) | 164 (47.8) | 1.05 (0.82–1.34) |
| Sex | |||
| Male | 2318 (52.5) | 992 (42.8) | Referent |
| Female | 2100 (47.5) | 1085 (51.7) | 0.97 (0.85–1.10) |
| Marital status | |||
| Married | 2571 (58.2) | 1190 (46.3) | Referent |
| Unmarried | 1718 (38.9) | 828 (48.2) | 1.09 (0.96–1.25) |
| Unknown | 129 (2.9) | 59 (45.7) | 1.07 (0.73–1.56) |
| Tumor grade | |||
| Well/moderately differentiated | 2554 (57.8) | 1196 (46.8) | Referent |
| Poorly/undifferentiated | 1148 (26.0) | 542 (47.2) | 1.04 (0.90–1.21) |
| Unknown | 716 (16.2) | 339 (47.3) | 1.03 (0.86–1.23) |
| Comorbidity Scores | |||
| 0 | 2357 (53.4) | 1122 (47.6) | Referent |
| 1 | 1280 (29.0) | 585 (45.7) | 0.85 (0.73–0.98)* |
| 2 | 430 (9.7) | 211 (49.1) | 1.00 (0.80–1.25) |
| ≥3 | 351 (7.9) | 159 (45.3) | 0.80 (0.63–1.01) |
| Metastasis | |||
| Liver | 2969 (67.2) | 1476 (49.7) | 1.14 (0.93–1.38) |
| Lung | 730 (16.5) | 358 (49.0) | 1.06 (0.89–1.26) |
| Abdomen | 873 (19.8) | 423 (48.5) | 1.00 (0.83–1.20) |
| Other | 696 (15.8) | 304 (43.7) | 0.77 (0.64–0.92)* |
| Unknown | 747 (16.9) | 283 (37.9) | 0.68 (0.52–0.88)* |
| Cancer site | |||
| Colon | 3276 (74.2) | 1618 (49.4) | Referent |
| Rectal | 1142 (25.9) | 459 (40.2) | 0.69 (0.59–0.80)* |
| SES (poverty) | |||
| 1st (low SES) | 989 (22.4) | 457 (46.2) | Referent |
| 2nd | 1070 (24.2) | 504 (47.1) | 1.07 (0.89–1.29) |
| 3rd | 1139 (25.8) | 549 (48.2) | 1.13 (0.93–1.37) |
| 4th (high SES) | 1220 (27.6) | 567 (46.5) | 1.10 (0.89–1.35) |
| Region | |||
| Midwest | 566 (12.8) | 247 (43.6) | Referent |
| North east | 1000 (22.6) | 443 (44.3) | 0.95 (0.76–1.20) |
| South | 1035 (23.4) | 533 (51.5) | 1.31 (1.05–1.64)* |
| West | 2969 (67.2) | 854 (47.0) | 1.06 (0.86–1.32) |
| Urban/rural | |||
| Less urban/rural | 477 (10.8) | 210 (44.0) | Referent |
| Urban | 268 (6.1) | 126 (47.0) | 1.24 (0.90–1.71) |
| Metro | 3672 (83.1) | 1741 (47.4) | 1.29 (1.03–1.61)* |
| Year of diagnosis | |||
| 2004 | 731 (16.6) | 112 (15.3) | Referent |
| 2005 | 696 (15.8) | 368 (52.9) | 6.55 (5.09–8.44)* |
| 2006 | 780 (17.7) | 447 (57.3) | 7.62 (5.93–9.78)* |
| 2007 | 722 (16.3) | 391 (54.2) | 6.70 (5.20–8.62)* |
| 2008 | 752 (17.0) | 376 (50.0) | 5.80 (4.51–7.45)* |
| 2009 | 737 (16.7) | 383 (52.0) | 6.21 (4.83–7.98)* |
CI confidence interval, mCRC metastatic colorectal cancer, OR odds ratio, SES socio-economic status
* Significant at α = 0.05